A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.
Key Takeaways
-
States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.
The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent...








